Status:
COMPLETED
BTT1023 in Psoriasis
Lead Sponsor:
Biotie Therapies Corp.
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of B...
Eligibility Criteria
Inclusion
- Plaque psoriasis affecting at least 8% of the body surface area and scoring 8 or higher in the psoriasis area and severity index
Exclusion
- Seropositive for infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus; Tuberculosis; Acute systemic infection;
- Treatment with a monoclonal antibody therapy within 12 weeks prior to study entry;
- An absolute indication for a known effective treatment
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00871598
Start Date
March 1 2009
End Date
August 1 2010
Last Update
November 16 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Biotie investigational site
Dresden, Dresden, Germany, 01067
2
Biotie investigational site
Leipzig, Leipzig, Germany, 04103
3
Biotie investigational site
Berlin, State of Berlin, Germany, 12627
4
Biotie investigational site
Berlin, State of Berlin, Germany, 14050